GlaxoSmithKline blood cancer treatment meets primary objective in clinical trial

Writer, Stock Market Wire
Friday, August 23, 2019 - 07:16

GlaxoSmithKline said a clinical study of its blood cancer treatment had met its primary goal.

'The two-arm study met its primary objective and demonstrated a clinically meaningful overall response rate with belantamab mafodotin in the patient population, the company said. 'The safety and tolerability profile was consistent with that observed in DREAMM-1, the first time in human study of belantamab mafodotin.'

The data from the study would be the basis for regulatory filings starting later this year,' it added.

'I am pleased with the results of the DREAMM-2 study and excited about what these data could mean for patients with multiple myeloma who have exhausted other lines of treatment,' said Dr Hal Barron, Chief Scientific Officer and President R&D, GSK .

Related content

Broker Forecast - Deutsche Bank issues a broker note on GlaxoSmithKline PLC

Deutsche Bank today reaffirms its hold investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1645p (from 1620p).

Broker Forecasts data provided...

Mon, 02/09/2019 - 08:50

Temple Bar could outperform if markets turn sour


Investors seeking a portfolio of cheap, dividend-paying stocks and selling on a 6.3% discount to net asset value (NAV) should look to Temple Bar Investment...

Thu, 29/08/2019 - 00:00

GlaxoSmithKline's JV ViiV Healthcare says trial of injectable HIV treatment met objectives

ViiV Healthcare, a GlaxoSmithKline-Pfizer joint venture, said its injectable HIV treatment had met its primary goal in a clinical trial, reducing the number of treatments...

Thu, 22/08/2019 - 07:41

GlaxoSmithKline submits renal anaemia drug application in Japan

GlaxoSmithKline said it had submitted an application for a drug that treats renal anaemia in patients with chronic kidney disease to the Japanese health regulator....

Wed, 21/08/2019 - 08:58

Ideagen is a structural growth story with plenty of opportunity


If the 10-year run of global economic expansion really is winding down then it makes sense for investors to look for structural growth drivers and...

Thu, 15/08/2019 - 00:00